Effects of different light sources on the stability of cinepazide maleate in sodium chloride solution / 中国基层医药

Objective:To investigate the effects of different light sources on the stability of cinepazide maleate in sodium chloride solution, providing a theoretical basis for standardizing operation for avoiding light in clinical medication.Methods:First, a standard curve was created and methodological studies were conducted. Then, intravenous drip solutions were prepared using clinically prescribed methods. Then, the absorbance of the solution of cinepazide maleate injection under outdoor light, light emitting diode (LED) light, indoor light, artificial sunlight with a color temperature of 6 500 K (D65), and under a shading condition for 1, 2, 3, and 7 hours were brought into the standard curve to obtain the concentrations, and the change of the concentrations was studied.Results:There was no light decomposition phenomenon of cinepazide maleate injection in the shading group (control group) within 7 hours. In the other four experimental groups, there was no obvious light decomposition phenomenon of cinepazide maleate injection in the LED light group. Compared with the shading group, cinepazide maleate injection in the indoor, outdoor, and D65 groups began to exhibit a light decomposition phenomenon at 1 hour ( F = 44 840.44, P < 0.001). At 2 hours, cinepazide maleate content in the outdoor and D65 groups began to decrease significantly compared with the shading group ( F = 15 459.12, P < 0.001). At 7 hours, cinepazide maleate exhibited significantly greater light decomposition in the outdoor group [(29.84 ± 0.43) L·mol -1·cm -1] and D65 group [(21.01 ± 0.51) L·mol -1·cm -1] than the shading group [(101.65 ± 1.5) L·mol -1·cm -1] ( F = 63 106.32, P < 0.001). There was no significant difference in cinepazide maleate content between LED and shading groups ( P > 0.05). Conclusion:Cinepazide maleate injection is stable under the common LED light source and therefore it is not necessary to take lightproof operation. Cinepazide maleate injection is unstable under indoor, outdoor, and D65 light sources, and it is necessary to take lightproof operation.

Exploring the treatment of sepsis-associated acute lung injury with Liangge Powder via ERK1/2 and PI3K/AKT pathways: based on network pharmacology and whole animal experimentation / 中华劳动卫生职业病杂志

Objective: To investigate the therapeutic effect and mechanism of Liangge Powder against sepsis-induced acute lung injury (ALI) . Methods: From April to December 2021, the key components of Liangge Powder and its targets against sepsis-induced ALI were analyzed by network pharmacology, and to enrich for relevant signaling pathways. A total of 90 male Sprague-Dawley rats were randomly assigned to sham-operated group, sepsis-induced ALI model group (model group), Liangge Powder low, medium and high dose group, ten rats in the sham-operated group and 20 rats in each of the remaining four groups. Sepsis-induced ALI model was established by cecal ligation and puncture. Sham-operated group: gavage with 2 ml saline and no surgical treatment. Model group: surgery was performed and 2 ml saline was gavaged. Liangge Powder low, medium and high dose groups: surgery and gavage of Liangge Powder 3.9, 7.8 and 15.6 g/kg, respectively. To measure the wet/dry mass ratio of rats lung tissue and evaluate the permeability of alveolar capillary barrier. Lung tissue were stained with hematoxylin and eosin for histomorphological analysis. The levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL) -6 and IL-1β in bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay. The relative protein expression levels of p-phosphatidylinositol 3-kinase (PI3K), p-protein kinase B (AKT), and p-ertracellular regulated protein kinases (ERK) were detected via Western blot analysis. Results: Network pharmacology analysis indicated that 177 active compounds of Liangge Powder were selected. A total of 88 potential targets of Liangge Powder on sepsis-induced ALI were identified. 354 GO terms of Liangge Powder on sepsis-induced ALI and 108 pathways were identified using GO and KEGG analysis. PI3K/AKT signaling pathway was recognized to play an important role for Liangge Powder against sepsis-induced ALI. Compared with the sham-operated group, the lung tissue wet/dry weight ratio of rats in the model group (6.35±0.95) was increased (P<0.001). HE staining showed the destruction of normal structure of lung tissue. The levels of IL-6 [ (392.36±66.83) pg/ml], IL-1β [ (137.11±26.83) pg/ml] and TNF-α [ (238.34±59.36) pg/ml] were increased in the BALF (P<0.001, =0.001, <0.001), and the expression levels of p-PI3K, p-AKT and p-ERK1/2 proteins (1.04±0.15, 0.51±0.04, 2.31±0.41) were increased in lung tissue (P=0.002, 0.003, 0.005). The lung histopathological changes were reduced in each dose group of Liangge Powder compared with the model group. Compared with the model group, the wet/dry weight ratio of lung tissue (4.29±1.26) was reduced in the Liangge Powder medium dose group (P=0.019). TNF-α level [ (147.85±39.05) pg/ml] was reduced (P=0.022), and the relative protein expression levels of p-PI3K (0.37±0.18) and p-ERK1/2 (1.36±0.07) were reduced (P=0.008, 0.017). The wet/dry weight ratio of lung tissue (4.16±0.66) was reduced in the high-dose group (P=0.003). Levels of IL-6, IL-1β and TNF-α[ (187.98±53.28) pg/ml, (92.45±25.39) pg/ml, (129.77±55.94) pg/ml] were reduced (P=0.001, 0.027, 0.018), and relative protein expression levels of p-PI3K, p-AKT and p-ERK1/2 (0.65±0.05, 0.31±0.08, 1.30±0.12) were reduced (P=0.013, 0.018, 0.015) . Conclusion: Liangge Powder has therapeutic effects in rats with sepsis-induced ALI, and the mechanism may be related to the inhibition of ERK1/2 and PI3K/AKT pathway activation in lung tissue.

Research progress in Guanxin Tongluo capsule for the treatment of coronary heart disease / 中国基层医药

Guanxin Tongluo capsule is a compound traditional Chinese medicine preparation for the treatment of coronary heart disease. The underlying mechanism may be related to expanding coronary artery, increasing coronary artery blood flow, reducing myocardial oxygen consumption, and decreasing whole blood viscosity, plasma viscosity, and hematocrit. This paper reviews the clinical research progress of Guanxin Tongluo capsule in the treatment of coronary heart disease from the aspects of etiology, pathogenesis, pharmacological research, and clinical research, providing evidence for scientific research and clinical application of Guanxin Tongluo capsule.

Orientaciones metodológicas para la impartición del tema Farmacocinética en tercer año de Medicina / Methodological guidelines for the teaching of the subject Pharmacokinetics in the third year of Medicine

RESUMEN Fundamento: la Farmacocinética es un tema que en Farmacología genera dificultades en los estudiantes debido a su complejidad, por lo que su impartición debe ser tratada en el colectivo de asignatura a través del trabajo metodológico. Objetivo: elaborar orientaciones metodológicas para el perfeccionamiento de la impartición del tema Farmacocinética en Farmacología I. Metodos: se realizó una investigación descriptiva transversal en la Universidad de Ciencias Médicas de Villa Clara de enero a junio de 2016. Fueron empleados como métodos teóricos: analítico-sintético, inducción-deducción y sistémico estructural-funcional; empíricos: análisis documental, la encuesta a estudiantes, entrevista a informantes clave y la tormenta de ideas como técnica participativa; y matemático-estadísticos. La investigación se desarrolló en tres etapas: diagnóstico, elaboración de las orientaciones metodológicas y la valoración por especialistas. Resultados: se constató que el insuficiente aprovechamiento del espacio de la consulta docente y la motivación de los alumnos por el estudio del tema fueron los factores que más influyeron en los deficientes resultados obtenidos, por lo que se fortaleció el trabajo metodológico del colectivo a través de la elaboración de orientaciones metodológicas que incluyeron una guía didáctica para favorecer el trabajo independiente. Conclusiones: las orientaciones metodológicas garantizaron un mejor desarrollo en la impartición del tema lo cual redundó en mejor apropiación de los conocimientos. Fueron avaladas por criterios de especialistas, quienes consideraron el producto como pertinente, útil, factible y con valor científico-pedagógico.

ABSTRACT Background: Pharmacokinetics is a subject that in Pharmacology generates difficulties in students due to its complexity, so that its teaching must be treated in the subject teaching staff meeting through methodological work. Objective: to develop methodological guidelines for the improvement of the teaching of the Pharmacokinetics subject in Pharmacology I. Methods: a cross-sectional descriptive research was carried out at Villa Clara University of Medical Sciences from January to June 2016. Theoretical methods were used: analytical-synthetic, induction-deduction and structural-functional systemic; empirical ones: documentary analysis, the student survey, interviews with key informants and brain-storming as a participative technique; and mathematical-statistics. The research was developed in three stages: diagnosis, preparation of methodological guidelines and assessment by specialists. Results: it was found that the insufficient use of the space of the teaching consultation class and the motivation of the students for the study of the subject were the factors that most influenced the poor results obtained, so the methodological work of the subject teaching staff meeting was strengthened through the elaboration of methodological guidelines that included a didactic guide to favor the independent work. Conclusions: the methodological guidelines ensured a better development in the teaching of the topic, which resulted in better appropriation of knowledge. They were endorsed by specialists, who considered the product as pertinent, useful, feasible and with scientific-pedagogical value.

Interações entre fármacos e nutrientes: ocorrência e manejo clínico / Interactions between pharmaceuticals and nutrients: occurrence and management clinic

Introdução: a dieta alimentar fornece nutrientes necessários ao sustento do corpo humano, portanto alterações provocadas por doenças e infecções, levam à utilização de medicamentos, o qual o uso associado pode interferir na eficácia terapêutica. Objetivo: Apresentar o manejo clínico, a ocorrência e os diversos aspectos da interação fármaco-nutriente. Metodologia: revisão integrativa da literatura, a qual foi utilizado as bases de dados para a busca dos artigos: BVS, MEDLINE, PubMed, LILACS e SciELO, com as palavras-chaves selecionados nos Descritores em Ciências da Saúde (DeCS) da Bireme: interações alimento-droga, medicamentos, clinica. Foram incluídas pesquisas que abordam a ocorrência de interações de fármacos com nutrientes alimentares e a descrição do manejo clinico, dentre estudos de casos, revisões e pesquisas clinicas, publicados em inglês, português ou espanhol no período de 2008 a 2016. Resultados: na administração de medicamento com um alimento existe a possibilidade de alterações na farmacodinâmica ou na farmacocinética da droga ou do nutriente, alterando o estado nutricional ou a resposta terapêutica. No geral, as estratégias adotadas devem ser peliculares a cada situação levando em consideração a condição clínica do indivíduo e as características do fármaco em utilização associadas as necessidades metabólicas do organismo envolvido. Como no caso da interação de levodopa com aminoácidos, que pode ser adotado a esquematização dos horários da dieta, tendo em vista à administração da maior composição proteica à noite. Conclusão: evidencia-se o contexto dinâmico no manejo clinico de interações e a necessidade da equipe multiprofissional para uma indicação de intervenções cabíveis para melhorar a vida da população

Inhibidores del receptor plaquetario P2Y12. Parte 1 de 2: escenario de acción, farmacología, aplicación clínica y limitaciones de su uso / Platelet P2Y12 receptor inhibitors. Part 1 of 2: Scenario of action, pharmacology, clinical application, and limitations of its use

Resumen: las enfermedades cardiovasculares, incluidas las afecciones del corazón, del cerebro y de los vasos sanguíneos en general, representan la primera causa de muerte a nivel mundial, con diecisiete millones y medio de muertes cada año. La prevención primaria y secundaria de las enfermedades aterotrombóticas, como el infarto agudo de miocardio, el accidente cerebrovascular y las enfermedades trombóticas, además de las medidas generales para el control de los factores de riesgo tales como la obesidad, el sedentarismo, el tabaquismo, la hipertensión arterial y la diabetes, se han centrado en el control de la agregación plaquetaria. El antiagregante plaquetario por excelencia o universal, sobre todo en la prevención primaria, es la aspirina y la terapia dual con la combinación de aspirina y un inhibidor del receptor plaquetario P2Y12, principalmente el clopidogrel, es usada en la prevención secundaria y en los casos de resistencia a la aspirina. En el momento, se dispone para uso clínico de seis inhibidores del receptor plaquetario P2Y12: la ticlopidina, el clopidogrel, el prasugrel, el ticagrelor, el cangrelor y el elinogrel. En este primer módulo, de dos que serán presentados, se abordará el uso de los inhibidores del receptor plaquetario P2Y12 en la práctica del día a día en la prevención primaria y secundaria de las enfermedades aterotrombóticas, enfocado en el análisis del papel de las plaquetas en la fisiopatología de la enfermedad aterotrombótica y la descripción de los seis inhibidores del receptor plaquetario P2Y12 disponibles ahora y en el futuro. En un segundo módulo se hará una aproximación al concepto de la resistencia a los inhibidores del receptor plaquetario P2Y12, su diagnóstico desde el punto de vista del laboratorio y las diferentes alternativas de manejo cuando se presenta resistencia a uno de estos medicamentos. (AU)

Abstract: Cardiovascular diseases, including in general heart diseases, brain, and blood vessels are the leading cause of death worldwide with 17.000.000 of deaths each year. Primary and secondary prevention of atherothrombotic diseases, as acute myocardial infarction, stroke, and thrombotic disorders, besides to the general measures for risk factors control such as obesity, sedentary lifestyle, smoke, high blood pressure, and diabetes, have focused on platelet aggregation control. The antiplatelet agent par excellence or universal, especially in primary prevention, is aspirin, and dual therapy with the combination of aspirin and a platelet receptor inhibitor P2Y12, with clopidogrel as the most used, for secondary prevention and in cases of aspirin resistance. Currently, six P2Y12 platelet receptor inhibitors are available for clinical use: ticlopidine, clopidogrel, prasugrel, ticagrelor, cangrelor, and elinogrel. In this first of two modules, the use of P2Y12 receptor inhibitors in daily practice in the primary and secondary prevention of atherothrombotic diseases will be addressed focused on the analysis of the platelets role in atherothrombotic disease pathophysiology and description of the six P2Y12 platelet receptor inhibitors available now and in the future. In a second module, we will approach the concept of resistance to platelet P2Y12 receptor inhibitors, its diagnosis from the laboratory point of view and the different management alternatives when resistance to one of these drugs is present. (AU)

Los ensayos clínicos y su impacto en la sociedad / Clinical Trials and their Impact on Society

En la actualidad son incontables los ejemplos que ilustran la naturaleza de la tecnociencia, entre ellos tenemos la biotecnología y la farmacología. El ensayo clínico constituye la metodología idónea que utiliza la farmacología clínica para evaluar la eficacia y seguridad de un tratamiento o intervención en seres humanos, este constituye la piedra angular de la investigación. En la actualidad, uno de los mayores retos que enfrenta la Industria Médico Farmacéutica y Biotecnológica cubana, una vez transcurrida la etapa de investigación preclínica, es justamente la etapa de evaluación clínica. Por lo cual este trabajo tiene como objetivo ofrecer una reflexión sobre los aspectos más significativos de los ensayos clínicos y su impacto en la sociedad.

Today there are countless examples that illustrate the nature of technoscience, including biotechnology and pharmacology. The clinical trial is the appropriate methodology used by clinical pharmacology to test the efficacy and safety of a treatment or intervention in humans. It constitutes the cornerstone of research. Once the preclinical research is completed, one of the biggest challenges currently facing the Cuban Pharmaceutical and Biotechnological Industry is precisely the clinical evaluation. Therefore, this work aims to provide a reflection on the most significant aspects of clinical trials and their impact on society.

Diferenças dos betabloqueadores no tratamento da hipertensão arterial / Beta-blockers differences in the treatment of hypertension

Os betabloqueadores vêm sendo usados a um longo tempo no tratamento da hipertensão arterial. Os estudos comparativos recentes têm demonstrado uma menor eficácia de alguns deles, como o Atenolol, na prevenção de eventos em pacientes hipertensos. Os betabloqueadores apresentam diferenças farmacológicas que podem se traduzir em diferenças em efeitos e eficácia clínica. Este artigo revisa a farmacologia clínica comparativa dos betabloqueadores, ensaios clínicos e metanálises na tentativa de fornecer uma base racional no tratamento da hipertensão arterial.

Beta-blockers have been used for a long time in the treatment of arterial hypertension. Recent controlled trials have shown a reduced efficacy in events prevention of some of them, like Atenolol. Betablockers have pharmacologic characteristics that can lead to differences in effects and probably in efficacy. This article compares the clinical pharmacology of beta-blocker agents, clinical trials and metaanalysis to support their judicious use in hypertension treatment.

Avaliação farmacodinâmica e análise físico-química de duas formulações de propofol usadas em infusão alvo-controlada / Pharmacodynamic evaluation and physical/chemical analysis of two formulations of propofol used in target-controlled infusion / Evaluación farmacodinámica y análisis físico-químico de dos formulaciones de propofol usadas en infusión objeto-controlada

JUSTIFICATIVA E OBJETIVOS: Existem várias formulações de propofol para uso clínico à disposição do anestesiologista. O objetivo desse estudo foi analisar as propriedades físico-químicas, o efeito farmacodinâmico e a equivalência farmacêutica e clínica do fármaco referência de propofol e uma formulação similar. MÉTODOS: Dezesseis voluntários participaram desse estudo aleatório, duplamente encoberto e pareado entre as formulações Diprivan® e Propovan®. As formulações foram administradas em regime de infusão alvo-controlada com concentração-alvo de 3,0 µg.mL-1 por 15 minutos. As variáveis estudadas foram a área sob a curva (ASC) do gráfico do índice bispectral (BIS) em relação ao tempo, o BIS mínimo atingido e o tempo para tal e o tempo de recuperação. As duas formulações foram submetidas às análises de tamanho de partículas da emulsão lipídica, potencial de superfície e quantificação de princípio ativo. RESULTADOS: Não houve diferença entre as formulações quando se comparou a ASC, BIS mínimo atingido e o tempo decorrido para tal. O tempo de recuperação com a formulação similar foi menor em relação à referência (oito e 10 min, respectivamente, p = 0,014). O tamanho médio de partículas da emulsão lipídica, potencial de superfície e a quantificação de princípio ativo foram semelhantes nas duas formulações. CONCLUSÃO: Não houve diferença clínica significativa entre o uso de propofol referência Diprivan® e seu similar Propovan® durante a infusão. Entretanto, o tempo de recuperação foi mais prolongado com o fármaco referência. Embora as análises com as duas formulações estudadas mostrarem resultados semelhantes quanto a sua caracterização físico-química, outros estudos devem ser realizados para justificar tal diferença.

BACKGROUND AND OBJECTIVES: There are several formulations of propofol available to the anesthesiologist for clinical use. The aim of this study was to analyze the physicochemical properties, pharmacodynamic effect, and pharmaceutical and clinical equivalence of the reference drug propofol as well as a similar formulation. METHOD: Sixteen volunteers were enrolled in this randomized, double-blind, and paired study of Diprivan® and Propovan® formulations. Formulations were given as target-controlled infusion with target concentration of 3.0 μg.mL-1 for 15 minutes. Variables studied were the area under the curve (AUC) of the bispectral index (BIS) graph regarding time, minimum BIS reached and time to reach it, and recovery time. The two formulations were sent to analysis of particle size of lipid emulsion, surface potential, and active principle quantification. RESULTS: There was no difference between the formulations when comparing AUC, minimum BIS reached and time to reach it. The similar formulation recovery time was lower compared to the reference formulation (eight and 10 min, respectively, p = 0.014). Mean particle size of lipid emulsion, surface potential, and active ingredient quantification were similar for both formulations. CONCLUSION: There was no clinically significant difference between the use of propofol, reference Diprivan®, and the similar Propovan® during infusion. However, the recovery time was longer with the reference drug. Although analysis of both formulations studied show similar results regarding its physicochemical characterization, further studies should be conducted to justify this difference.

JUSTIFICATIVA Y OBJETIVOS: Existen varias formulaciones de propofol para el uso clínico que están disponibles para el anestesiólogo. El objetivo de este estudio, fue analizar las propiedades físico-químicas, el efecto farmacodinámico y la equivalencia farmacéutica y clínica del fármaco referencia de propofol y una formulación similar. MÉTODO: Dieciséis voluntarios participaron en este estudio aleatorio, doble ciego y pareado entre las formulaciones Diprivan® y Propovan®. Las formulaciones fueron administradas en un régimen de infusión objeto-controlada con una concentración objetivo de 3,0 µg.mL-1 durante 15 minutos. Las variables estudiadas fueron el área bajo la curva (ASC) del gráfico del índice bispectral (BIS) con relación al tiempo, el BIS mínimo alcanzado y el tiempo para tal, y el tiempo de recuperación. Las dos formulaciones se sometieron a los análisis de tamaño de partículas de la emulsión lipídica, potencial de superficie y cuantificación del principio activo. RESULTADOS: No hubo diferencia entre las formulaciones cuando se comparó la ASC, el BIS mínimo alcanzado y el tiempo transcurrido para tal. El tiempo de recuperación con la formulación similar fue menor con relación a la referencia (8 y 10 min, respectivamente, p = 0,014). El tamaño promedio de partículas de la emulsión lipídica, potencial de superficie y la cuantificación del principio activo, fueron similares en las dos formulaciones. CONCLUSIONES: No hubo diferencia clínica significativa entre el uso de propofol referencia Diprivan® y su similar Propovan® durante la infusión. Sin embargo, el tiempo de recuperación se extendió más con el fármaco de referencia. Aunque los análisis de las formulaciones estudiadas muestren resultados similares en cuanto a su caracterización físico-química, otros estudios deben ser realizados para justificar tal diferencia.

Effects of different methods of administration on clinical pharmacodynamics of cisatracurium during liver transplantation / 中华麻醉学杂志

Objective To evaluate the effects of different methods of administration on clinical pharmacodynamics of cisatracurium during liver transplantation.Methods Twenty-four ASA physical status Ⅲ patients of both sexes,aged 18-63 yr,weighing 60-88 kg,with body mass index of 20-30 kg/m2,scheduled for elective liver transplantation,were randomly divided into 2 groups (n =12 each):continuous infusion group (group C) and intermittent bolus injection group (group Ⅰ).The total intravenous anesthesia was used during surgery.When T1 recovered to 10％ of control height after induction of anesthesia,continuous infusion of cisatracurium was started with an initial rate of 1.5 μg· kg-1 · min-1,and the infusion rate was manually adjusted to maintain T1 at about 10％ in group C,and intermittent iv boluses of cisatracurium 0.03 mg/kg were given to maintain T1 ≤ 10％ in group Ⅰ.The use of muscle relaxants was stopped immediately after peritoneum closure.The consumption of cisatracurium per minute,time for T1 to recover from 10％ to 25％,recovery index and time for recovery of spontaneous breathing after surgery were recorded.Results Compared with group Ⅰ,the consumption of cisatracurium per minute was significantly reduced and the time for recovery of spontaneous breathing after surgery was shortened (P ＜ 0.05),and no significant changes were found in the time for T1 to recover from 10％ to 25％ and recovery index in group C (P ＞ 0.05).Conclusion Compared with intermittent bolus injection,continuous infusion of cisatracurium during liver transplantation is helpful in improving the clinical potency of the muscle relaxant and in reducing the occurrence of complications during anesthesia recovery period.

Establishment of pharmacodynamic model of sevoflurane in pediatric patients: bispectral index / 中华麻醉学杂志

Objective To establish the pharmacodynamic model of sevoflurane with bispectral index (BIS) as the effective index in pediatric patients.Methods Thirteen ASA physical status Ⅰ or Ⅱ pediatric patients,aged 4-9 yr,weighing 12-39 kg,undergoing non-cardiac surgery,were selected in the study.The pediatric patients sequentially inhaled 1％,5 ％ and 1％ sevoflurane via a face mask and each concentration was inhaled for 15 min.BIS value,HR,BP and SpO2 were automatically recorded every 10 s.Based on nonlinear mixed effect modeling,the population pharmacodynamic model of sevoflurane was established using NONMEM software.The effect of age on the pharmacodynamic parameters was evaluated using a stepwise forward addition then backward elimination modeling approach.The standard for model improvement was defined as a decrease in the value of the objective function by more than 3.84.Results Twelve pediatric patients,aged 4.0-8.5 yr,weighing 12.8-38.0 kg,with body height of 92-135 cm,were enrolled in this study and the data which were enrolled comprised 2964 effective concentration-time-BIS points.The model was not improved significantly with any covariates (age,body height,and body weight) introduced (P ＞ 0.05).The estimated parameters of the final pharmacodynamic model of sevoflurane were as follows:ke0 =O.516/min ; EC50 (BIS50) =2.11％ ; γ =2.46 ; E0 =74.6 ; EMAx =11.2.Conclusion The pharmacodynamic model of sevoflurane is successfully established with BIS as the effective index in pediatric patients,and the analysis for each parameter of the model indicates that the sensitivity to sevoflurane is lower,but the blood-brain equilibration time of the drug is shorter and the onset and recovery are faster in children than in adults.

Clinical Significance of Home Blood Pressure and Its Possible Practical Application

This review represents the clinical significance of home blood pressure (BP) and its possible practical application. Home BP is highly reproducible and its reproducibility is better than ambulatory BP. According to this feature home BP has a greater prognostic value at least than clinic BP and is extremely effective for the evaluation of drug effects and their duration. The introduction of home BP to the diagnosis and treatment of hypertension facilitates long-term BP control. Home BP is particularly important for the diagnosis and treatment of hypertension in diabetes mellitus, pregnancy, children and renal diseases. Home BP measurements improve the adherence to medications and medical consultations, and are indispensable for diagnosis of white coat hypertension and masked hypertension. Such efficiency of home BP improves medical economy. Home BP can detect minimal charge in BP mediated by medication, and intrinsic and extrinsic stimuli and detect long-term change in BP. Thus, home BP is now indispensable for improvement in the management of hypertension in medical practice as well as for the recognition of hypertension in the general population. Standardization of the measurement procedure may elevate the position of home BP in the practice of diagnosing and treating hypertension.

RP-HPLC determination of ferulate acid in the compound angelica scinensis pian / 中国基层医药

Objective To determine ferulate acid in the compound angelica scinensis particle by RP-HPLC method.Methods The liquid chromatography was carried out using Zorbax C_ 18 (5?m,4.6mm?250mm),with detection wavelength at 320nm.The flow rate of mobile phase[5% acetic acid-methanol(75∶25)] was 1ml/min.Results The calibration curve was linear in the range of 0.0141～0.450mg/ml(r=0.9997,n=5).The average recoveries was 94.87%(RSD=0.5%).Conclusion The method establishied in this paper can be adopt for the compound angelica scinensis particle.This method is simple,accurate,reliable and reproducible.

Pharmacokinetics of oral FK506 in patients after renal transplantation / 中华泌尿外科杂志

Objective To carry out a pharmacokinetic evaluation of oral FK506 in 13 patients after renal transplant. Methods 13 patients after renal transplantation were given prograf based immunosupressive regimen 24 hours after surgery.Blood samples to determine FK506 levels were drawn in heparinized tube at 0、20、40、60、90 min and 2、3、6、8、10 hours after the first oral dosing.The whole blood concentrations were measured by MEIA and the pharmacokinetic parameters were calculated by 3P87 program.The FK506 doses were recorded in detail for the first month. Results Cmax was (13.6259?4.1117)ng/ml;T(peak) was (1.4866?1.0725)h;t1/2 ? was (0.7749?0.7791)h,t1/2 ? was (10.7267?10.4926)h;AUC was (91.0415?40.7694)ng?ml -1 ?h -1 ,CL was (0.046?0.0036)ng?ml -1 ?h -1 and MRT was (8.1540?4.2937)h.AUC was negative correlateld with prograf dose in the first month posttransplant (r=-0.53, P =0.038). Conclusions The absorption of oral administration of FK506 was rapid in patients after renal transplantation,and can achieve Cmax in (1.5?1.1)h,the mean half life time being 10.7 h.The pharmacokinetic parameters can be the guideline for FK506 application.

THE PREPARATION, PROPERTIES AND CLINICAL USE OF d-KETAMINE HYDRO-CHLORIDE / 第二军医大学学报

In this paper, we reported the method and the results for resolution of d-keta-mine hydrochloride with DTA reagent .The optical purity of d-ketamine hydrochlori-de is coordinative with its standard compound.The yield is 35% based on d-ketamine hydrochloride.This compound had been used in 43 patients clinically and obtained good results The dosage was rather smaller and lesser side effects, such as illusion,eyeball quiver and muscular tension. Especially, when the drug is used with pethdine and promet-hazine as complex anesthesia,patients will get better effect. Although the blood pressure and heart rate of patients slightly increased, it is suitable to patients with bleeding and wound.